The heatmap of two types high alcohol use-related Stroke showing ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) across 21 GBD regions... by Nannan Qian (10650782)

Subjects:

Health inequality regression curves and concentration curves for the DALYs of two types of high alcohol use-related Stroke worldwide, 1990 and 2021. by Nannan Qian (10650782)

Subjects:

Population-level determinant changes in aging, population growth, and epidemiological changes for two types of high alcohol use-related Stroke DALYs globally and in various SDI reg... by Nannan Qian (10650782)

Subjects:

ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) of high alcohol use-related Stroke in both sexes combined in global in 2021. by Nannan Qian (10650782)

Subjects:

ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) of high alcohol use-related Stroke in both sexes combined in global and five SDI region... by Nannan Qian (10650782)

Subjects:

The EAPC of ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) of high alcohol use-related Stroke in both sexes combined across 21 GBD reg... by Nannan Qian (10650782)

Subjects:

The age-specific burden of high alcohol use-related Stroke, death and ASMR (A), DALYs and ASDR (B), YLDs and Age-Standardized Rate of YLDs (C), YLLs and Age-Standardized Rate of YL... by Nannan Qian (10650782)

Subjects:

ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) for two types of high alcohol use-related Stroke in both sexes combined globally, 1990–... by Nannan Qian (10650782)

Subjects:

ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) of high alcohol use-related Stroke in males and females across 21 GBD regions and SDI r... by Nannan Qian (10650782)

Subjects:

Frontier analysis exploring the relationship between SDI and DALYs for two types of high alcohol use-related Stroke in 204 countries and territories. by Nannan Qian (10650782)

Subjects:

No significant differences in the numbers of eggs between Mst1^+/+ and Mst1^ΔM/ΔM mice. by Jianyang Li (461703)

Data Sheet 1_What should we focus on in pregnancy complicated by pheochromocytoma? a bibliometric analysis (1990-2024).pdf by Shiyun Deng (21734750)

Data Sheet 1_Changes of brain structure and structural covariance networks in Parkinson’s disease with different sides of onset.docx by Tianqi Xu (9574329)

“…</p>Results<p>In patients with LPD, we found reduced CSA in the right supramarginal gyrus (SMG), right precuneus (PCUN), left inferior parietal lobule (IPL), and left lingual gyrus (LING) compared to RPD, while no significant differences in CT were found between the two groups. …”

Data Sheet 1_Assessing ecological environmental quality and conservation effectiveness in the World’s largest urban green heart using the remote sensing ecological index (RSEI) and... by Chongbo Wu (22135075)

Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

“…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”

Table 1_Elevated CO2 decreases micronutrient Zn but not Fe in vegetables – evidence from a meta-analysis.docx by Xiaolin Wang (303612)

Table 1_Higher oxidative balance score is associated with a decreased risk of infertility: an analysis of NHANES 2013–2020.docx by Mingjun Ma (11518765)

Data Sheet 1_A synonymous mutation of rs1137070 cause the mice Maoa gene transcription and translation to decrease.pdf by Kai Xin Li (19696741)

<i>In vivo</i> treatment decreases bacterial burden and colonization of vital organs in a skin abscess biofilm infection model. by Robert L. Beckman I.V (22784303)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”